Answer
Yes, breastfeeding should be discontinued during ibrutinib (Imbruvica) treatment because excretion of ibrutinib or its metabolites into human milk is unknown and a risk to breastfed children cannot be excluded.
Sources for this answer
- IMBRUVICA 140 mg film-coated tablets (Great Britain)Janssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 25Document updated
Sources checked